Peptide · Fact sheet

Teduglutide

Also known as Gattex · Revestive · GLP-2 analog

Teduglutide is FDA approved as Gattex for adults and children 1 year and older with short bowel syndrome who depend on parenteral support. It is not approved for routine gut health, inflammatory bowel disease, food intolerance, or wellness.

FDA approved for specific usesStrong human evidence for approved uses

What is Teduglutide?

Teduglutide is a long-acting analog of glucagon-like peptide 2, a hormone that supports intestinal growth, blood flow, and absorption.

Its clinical endpoint is reduced need for parenteral nutrition or fluids in short bowel syndrome, not a vague measure of gut repair.

Benefits & claims

It is a strong example of a peptide improving organ function through tissue adaptation rather than weight or hormone-release effects.

Its growth-promoting mechanism also explains important polyp, neoplasia, obstruction, and fluid-related safety concerns.

What the evidence supports

  • Controlled trials found that more participants reduced parenteral-support volume than with placebo.
  • Some long-term studies report further support reduction, but response varies and the therapy does not restore normal anatomy.
Research areas
  • Short bowel syndrome
  • Intestinal absorption
  • Parenteral-support reduction
  • Pediatric intestinal failure
  • Long-term intestinal autonomy and outcomes in selected intestinal-failure populations

Dosage & frequency

Product-specific label information

Gattex has a daily weight-based regimen for short bowel syndrome requiring parenteral support. Renal impairment changes the labeled amount.

Gattex

Adults and patients age one year and older with short bowel syndrome dependent on parenteral support

Amount
0.05 mg/kg; 0.025 mg/kg with eGFR below 60 mL/min/1.73 m²
Frequency
Once daily
Route studied or labeled
Subcutaneous

Monitoring and renal adjustment are integral to treatment.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The approved GLP-2 analog is not a general gut-repair supplement.

Interactions & precautions

  • Improved intestinal absorption can increase exposure to oral medicines, including medicines with a narrow therapeutic index.

What is still unresolved

  • Parenteral-support adjustments and monitoring cannot be inferred from the dose alone.

Side effects & risks

  • The label warns about accelerated neoplastic growth and requires attention to gastrointestinal polyps and malignancy risk.
  • Intestinal obstruction, biliary and pancreatic disease, and fluid overload are important labeled risks.
  • Increased absorption can change exposure to other oral medicines.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Randomized trials support reduced parenteral-support requirements in the labeled population. That evidence does not transfer to general digestive symptoms or unapproved gut-healing claims.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Weight: reported experiences

Mixed account · personal report

Improved output and weight, with burdensome fatigue

A patient diary described thicker ostomy output and eventual weight gain, alongside fatigue, disrupted sleep, bloating and temporary hair shedding.

Reported use in this account

Product
Gattex
Amount
Not specified clearly
Frequency
Daily injections described, with a week-long pause
Route
Injection; specific route not stated
Duration
Three-month diary

Other exposures described: Lomotil; IV fluids

Short bowel syndrome, dehydration and poor nutrient absorption already affected energy and hair. Symptoms changed over several months; causation was not established.

Read the original accounts

Approval status

Gattex is FDA approved for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.

Approved uses

  • Treatment of short bowel syndrome with dependence on parenteral support in the age groups specified by the Gattex label

FDA approved for short bowel syndrome

Teduglutide is approved under the Gattex label for short bowel syndrome with parenteral-support dependence in specified age groups.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Very long-term malignancy and polyp outcomes
  • Which patients can achieve durable independence from parenteral support
  • How pediatric outcomes evolve across growth and development
  • Whether benefits persist after treatment ends

Summary

Gattex has a specific role in short bowel syndrome with parenteral-support dependence. Its evidence does not establish general gut-repair benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Gattex

    Current indication, warnings, adverse reactions, and clinical studies.

  2. pubmedRandomized teduglutide short bowel syndrome trial

    Controlled evidence for reduced parenteral nutrition and fluid requirements.

  3. pubmedPhase 3 and extension study in Japan

    Small longer-term study illustrating response durability and population limits.

How we assess sources · Suggest a correction